CARB-X announced Tuesday an award of up to $12.5 million to North Carolina-based Locus Biosciences to develop LBP-KP01, a CRISPR-Cas3-enhanced bacteriophage cocktail that targets recurrent urinary tract infections (UTIs) caused by K. pneumoniae.

Locus is also developing a CRISPR-engineered bacteriophage cocktail against recurrent UTIs caused by E. coli—a project that secured up to $77 million in September from the U.S. Biomedical Advanced Research and Development Authority.

The U.S. Biomedical Advanced Research and Development Authority (BARDA) announced two awards Wednesday for “advanced development” of investigational drugs targeting antibiotic-resistant infections.

Massachusetts-based Vedanta Biosciences scored up to $76.9 million ($7.4 million upfront) to complete an ongoing Phase 2 trial and continue clinical development of VE303—a novel, human microbiome-derived treatment for high-risk C. difficile infection. The drug becomes the second CARB-X-…